Proteinuria in adults with sickle-cell disease: The role of hydroxycarbamide(hydroxyurea) as a protective agent

International Journal of Clinical Pharmacy

Volumn 36, Issue 4, 2014, Pages 766-770

  Silva, Geraldo B ^a,b   Vieira, Ana Patrícia F ^a   Couto Bem, Amanda X ^a   Alves, Marília P ^a   Meneses, Gdayllon C ^a   Martins, Alice M C ^a   Araújo, Sonia M H A ^b   Libório, Alexandre V ^a   Daher, Elizabeth F ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF FORTALEZA   (Brazil)

Author keywords

Hydroxycarbamide; Kidney disease; Proteinuria; Renal function tests; Sickle cell disease; Tubular dysfunction

Indexed keywords

FOLIC ACID; HYDROXYUREA; PROTECTIVE AGENT; ANTISICKLING AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RENAL PROTECTION; SICKLE CELL ANEMIA; ULTRAFILTRATION; ANEMIA, SICKLE CELL; BLOOD; BRAZIL; COHORT ANALYSIS; DRUG EFFECTS; GLOMERULAR FILTRATION BARRIER; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY CONCENTRATING CAPACITY; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; PH; SEVERITY OF ILLNESS INDEX; UNIVERSITY HOSPITAL; URINE; YOUNG ADULT;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BRAZIL; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION BARRIER; GLOMERULAR FILTRATION RATE; HOSPITALS, UNIVERSITY; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYUREA; KIDNEY; KIDNEY CONCENTRATING ABILITY; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PROTEINURIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84905989896     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-014-9955-4     Document Type: Article

References (22)

1. Loureiro MM, Rozenfeld S. Epidemiology of sickle cell disease hospital admissions in Brazil. Rev Saúde Pública. 2005;39(6):943-9.
2. Josephs H. Clinical aspects of sickle cell anemia. Bull Johns Hopkins Hosp. 1928;43:397-8.
3. Keitel HG, Thompson D, Itano HA. Hyposthenuria in sickle cell anemia: a reversible renal defect. J Clin Invest. 1956;35(9):998-1007.
4. Crosley AP, Strickland WH. Renal function in sickle cell anemia - a case report and review of the literature. J Natl Med Assoc. 1961;53(1):39-40.
5. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009;122(6):507-12.
6. Abo-Zenah H, Moharram M, El Nahas AM. Cardiorenal risk prevalence in sickle cell hemoglobinopathy. Nephron Clin Pract. 2009;112(2):c98-106.
7. Da Silva GB Jr, Libório AB, Daher Ede F. New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy. Ann Hematol. 2011;90(12):1371-9.
8. Wang WC. Sickle cell anemia and other sickling syndromes. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means Jr RT. Wintrobe's clinical hematology, 12th edition. Philadelphia: Lippincott Williams and Wilkins, p. 1038-1082, 2009. ISBN: 978-0-7817-6507-7
9. Saunthararajah Y, Vichinsky EP. Sickle cell disease - clinical features and management. In: Hoffman - Hematology: basic principles and practice. Oxford: Churchill Livingstone, 5th edn, p. 577-601, 2008. ISBN: 978-0443067150.
10. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-31.
11. Brandow AM, Panepinto JA. Hydroxycarbamide use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3(3):255-60.
12. Ware RE. How I use Hydroxycarbamide to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300-11.
13. Brawley OW, Cornelius LJ, Edwards LR, Northington Gamble V, Green BL, Inturrisi C, et al. National institutes of health consensus development conference statement: hydroxycarbamide treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-8. (Pubitemid 351860825)
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
15. Lobo C. Sickle cell disease - a serious problem for public health worldwide. Rev Bras Hematol Hemoter. 2010;32(4):280-1.
16. Bartolucci P, Galactéros F. Clinical management of adult sicklecell disease. Curr Opin Hematol. 2012;19(3):149-55.
17. Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxycarbamide treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol. 2013;88(2):116-9.
18. Alvarez O, Lopez-Mitnik G, Zilleruelo G. Short-term follow-up of patients with sickle cell disease and albuminuria. Pediatr Blood Cancer. 2008;50(6):1236-9. (Pubitemid 351555549)
19. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxycarbamide therapy for children with sickle nephropathy. Pediatr Blood Cancer. 2005;45(7):982-5. (Pubitemid 41552170)
20. Sasongko TH, Nagalla S, Ballas SK. Angiotension-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Datab Syst Rev. 2013;3:009191.
21. Aleem A. Proteinuria in adult Saudi patients with sickle cell disease is not associated with identifiable risk factors. Saudi J Kidney Dis Transpl. 2010;21(5):903-8.
22. Silva Junior GB, Vieira AP, Couto Bem AX, Alves MP, Meneses GC, Martins AM, et al. Renal tubular dysfunction in sickle cell disease. Kidney Blood Press Res. 2013;38(1):1-10. Tecnológico